finance.yahoo.com
Negativefinance.yahoo.com ·
atricure q1 earnings call highlights 222315682
WB_1331_HEALTH_TECHNOLOGIESWB_621_HEALTH_NUTRITION_AND_POPULATIONWB_1362_MEDICAL_EQUIPMENTCRISISLEX_C03_WELLBEING_HEALTH
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedAtriCure's Q1 earnings show strong revenue growth driven by pain management (cryoSPHERE MAX) and open ablation. The company is a medical device maker focused on cardiac surgery. No direct commodity or supply chain scarcity is indicated; the impact is company-specific and sectoral (medical devices). The positive net income and reaffirmed guidance suggest margin expansion, but no broader commercial mechanism beyond the company's own performance.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue $141.2M, +14.3% YoY
- Adjusted EBITDA nearly doubled to $17.1M
- Net income turned positive ~$100k
- Pain management sales +28%, cryoSPHERE MAX ~70% account penetration
- BoxX-NoAF trial ~300/960 patients enrolled, full enrollment by end 2026